Q-omics provides the consensus-scored MIR200B profile across patient tissues and cancer cell-line models. MIR200B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR200B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MIR200B RNA expression shows 14,737 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRC, and THYM as cancer lineages where MIR200B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR200B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR200B survival associations across molecular data types. MIR200B RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR200B RNA expression–survival associations across cancer types. High MIR200B expression shows unfavorable associations in CESC, LIHC, UCEC, READ and THCA, but favorable associations in HNSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR200B RNA expression.
This table summarizes MIR200B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR200B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR200B shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in COAD, CHOL and STAD. The KIRC box plot shows higher MIR200B RNA expression in normal versus tumor tissue (log2 FC = −0.593, t-test p < 0.001).
This table shows molecular features associated with MIR200B in patient tissues and cancer cell lines. In patient samples, MIR200B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIR200B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
